Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Spreen

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|December 1, 2023
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the <i>vastus lateralis</i> (lateral thigh) muscles of healthy adult participantsKelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, et al.
Pharmacogenomics|March 16, 2004
Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsArlene R Hughes, Michael Mosteller, Aruna T Bansal, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 2, 2025
Cabotegravir pharmacokinetics in Asians with and without HIVKelong Han, Ahmed A Abulfathi, Rashmi S Mehta, et al.
AIDS (London, England)|December 1, 2016
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251Chasity D Andrews, Leslie St Bernard, Amanda Yee Poon, et al.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 3, 2015
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humansGary David Bowers, Amanda Culp, Melinda J Reese, et al.
Therapeutic Advances in Infectious Disease|December 18, 2023
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.
AIDS (London, England)|September 5, 2021
Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaquesSundaram Ajay Vishwanathan, Chunxia Zhao, Roopa Luthra, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|December 1, 2023
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the <i>vastus lateralis</i> (lateral thigh) muscles of healthy adult participantsKelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, et al.
Pharmacogenomics|March 16, 2004
Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populationsArlene R Hughes, Michael Mosteller, Aruna T Bansal, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 2, 2025
Cabotegravir pharmacokinetics in Asians with and without HIVKelong Han, Ahmed A Abulfathi, Rashmi S Mehta, et al.
AIDS (London, England)|December 1, 2016
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251Chasity D Andrews, Leslie St Bernard, Amanda Yee Poon, et al.
Science (New York, N.Y.)|March 6, 2014
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virusChasity D Andrews, William R Spreen, Hiroshi Mohri, et al.
HIV Clinical Trials|November 18, 2018
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trialMiranda I Murray, Martin Markowitz, Ian Frank, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 3, 2015
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humansGary David Bowers, Amanda Culp, Melinda J Reese, et al.
Therapeutic Advances in Infectious Disease|December 18, 2023
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.
AIDS (London, England)|September 5, 2021
Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaquesSundaram Ajay Vishwanathan, Chunxia Zhao, Roopa Luthra, et al.
The Patient|May 31, 2021
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)Vasiliki Chounta, Edgar T Overton, Anthony Mills, et al.
Pageof 5